• SPX
  • $5,737.03
  • 0.43 %
  • $24.34
  • DJI
  • $41,913.92
  • 0.29 %
  • $119.31
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,158.01
  • -0.32 %
  • -$26.23
  • IXIC
  • $18,283.25
  • 0.57 %
  • $103.26
Rezolute, Inc. (RZLT) Stock Price, News & Analysis

Rezolute, Inc. (RZLT) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.50

$0.06

(1.1%)

Day's range
$5.5
Day's range
$5.65
50-day range
$4.12
Day's range
$5.93
  • Country: US
  • ISIN: US76200L3096
52 wk range
$0.72
Day's range
$6.1
  • CEO: Mr. Nevan Charles Elam J.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 11.43
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (RZLT)
  • Company Rezolute, Inc.
  • Price $5.50
  • Changes Percentage (1.1%)
  • Change $0.06
  • Day Low $5.50
  • Day High $5.65
  • Year High $6.10

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/10/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $14.00
  • High Stock Price Target $15.00
  • Low Stock Price Target $11.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.14
  • Trailing P/E Ratio -5.02
  • Forward P/E Ratio -5.02
  • P/E Growth -5.02
  • Net Income $-68,459,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.